0%
complete
Final classification
VUS
PM2BP1
PALB2
c.2970A>T
p.Glu990Asp
missense · exon 9

PALB2 encodes a tumor suppressor protein that partners with BRCA2 (and also interacts with BRCA1) to repair double-stranded DNA breaks through the homologous recombination pathway. It acts as a scaffold that stabilizes BRCA2 in the cell nucleus and helps recruit DNA-repair machinery to sites of damage. Inherited mutations in PALB2 increase susceptibility to breast cancer, with smaller associated risks for ovarian, pancreatic, and prostate cancer and melanoma, and inheriting two mutated copies causes Fanconi anemia complementation group N. Rare somatic alterations in PALB2 are also found across various tumor types.

This variant

PALB2 is a tumor suppressor that partners with BRCA2 to repair double-stranded DNA breaks, and inherited alterations raise breast and other cancer risks. This missense change (p.Glu990Asp) is classified as a variant of uncertain significance because conflicting evidence neither establishes nor excludes pathogenicity, so it should not yet guide clinical decisions.

Transcript
NM_024675.4
HGVS · transcript:coding
NM_024675.4:c.2970A>T
GRCh38
chr16:23622995 T>A
GRCh37
chr16:23634316 T>A
VUS: conflicting evidence, with exactly one Pathogenic.Supporting criterion (PM2, gnomAD v4 AF=0) and one Benign.Supporting criterion (BP1, all missense variants) under VCEP v1.2 Rule 31.
Classification rationale
PM2 BP1 VUS
PALB2 c.2970A>T missense · exon 9

PM2 (Supporting): absent from gnomAD v4 (AF = 0), below the VCEP's <=1/300,000 (0.000333%) frequency threshold. BP1 (Supporting): the VCEP applies BP1 to all missense variants, and c.2970A>T is a confirmed missense change (p.Glu990Asp). Overall: VUS — Rule 31, conflicting evidence combining one Pathogenic.Supporting (PM2) and one Benign.Supporting (BP1) criterion.

PM2 + BP1 VUS
Gene diagram · NM_024675.4 · variants mapped to exon structure
PALB2 NM_024675.4
Fetching transcript structure from UCSC…
Applied criteria · 2 applied · 10 assessed
MetEvidence satisfies this criterion.
Not metEvaluated against available evidence; threshold not reached.
Not assessedApplies in principle, but no evidence was found to evaluate it.
N/ADoesn't apply to this variant type.
Applied · 2
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
Met (Supporting): absent from gnomAD v4 (AF=0), satisfying the VCEP frequency threshold of <=1/300,000 (0.000333%).
ClinGen HBOPC VCEP PALB2 v1.2 CSPEC PM2 rule: 'Frequency <= 1/300,000 (0.000333%) in gnomAD v4 dataset'; instructions specify 'Use as PM2_Supporting (not moderate)'.gnomAD v4.1 (GRCh38) lookup for chr16-23622995-T-A returned no variant record (search_status=absent), i.e., AF = 0, which is <= the 0.000333% PM2 threshold.Corroborating absence in gnomAD v2.1 (16-23634316-T-A) and gnomAD-Canada v1.0 (HostSeq genomes).
BP1 supporting Benign
Met (Supporting): the VCEP applies BP1 to all missense variants; this is a confirmed missense change (p.Glu990Asp).
PALB2 HBOP VCEP v1.2 (cspec) BP1 rule: 'Apply to all missense variants.' with default strength Benign Supporting.Variant normalization confirms a missense change: NP_078951.2:p.(Glu990Asp) from c.2970A>T; pvs1_variant_assessment consequence_class is 'missense'.
Assessed · not applied · 6 not met · 4 not assessed
Pathogenic
PVS1 Not met: missense substitution with no protein length change and no predicted splice impact (SpliceAI max delta 0.026, below the 0.2 threshold).
PS1 Not met: no predicted splice impact (SpliceAI max delta 0.026), so the VCEP's splicing-based PS1 does not apply.
PS4 Not assessed: no case-control or prevalence data existed to evaluate enrichment (threshold OR >=3, p <=0.05).
PM3 Not assessed: no proband, allele, or phase observations existed, so no Fanconi anemia PM3 points could be assigned.
PP1 Not assessed: no pedigree, LOD, or segregation data existed (Supporting requires LOD >=0.3), pending family studies.
PP3 Not met: SpliceAI max delta 0.026 is below the VCEP's 0.2 threshold, and missense in-silico predictors are barred for PP3.
Benign
BA1 Not met: absent from gnomAD v4 (AF=0), below the VCEP BA1 threshold of >0.1%.
BS1 Not met: absent from gnomAD v4 (AF=0), below the VCEP BS1 threshold of >0.01%.
BS2 Not met: no observed instances in healthy adults, so 0 BS2 points accrued (>=4 required for Strong).
BS4 Not assessed: no pedigree or segregation data existed to test lack of segregation (LOD <=-0.32 at Supporting).
N/A · 16 PS2 · PS3 · PM1 · PM4 · PM5 · PM6 · PP2 · PP4 · PP5 · BS3 · BP2 · BP3 · BP4 · BP5 · BP6 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
Absent from gnomAD v4.1.
v2.1
Absent from gnomAD v2.1.
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
gnomAD v2.1
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant is absent from ClinVar.
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.03). REVEL score = 0.014. BayesDel score = -0.568457.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. PALB2, a scaffolding protein involved in DNA repair, is altered in various cancers.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
9Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots